2137.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 11:08):

Stats
Dzisiejszy wolumen	2.81M
Średni wolumen	4.17M
Kapitalizacja rynkowa	926.64M
EPS	HKD0 ( 2024-03-25 )
Następna data zysków	( HKD0 ) 2024-06-25
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-4.88
ATR14	HKD0.00700 (0.56%)

Wolumen Korelacja

Długi: -0.15 (neutral)

Krótki: 0.48 (neutral)

Signal:(38.852) Neutral

Brii Biosciences Limited Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Brii Biosciences Limited Korelacja - Waluta/Towar

0.07
( neutral )

-0.09
( neutral )

0.00
( neutral )

0.34
( neutral )

0.00
( neutral )

-0.80
( strong negative )

Brii Biosciences Limited Finanse

Annual	2023
Przychody:	HKD617 000
Zysk brutto:	HKD55.89M (9 058.51 %)
EPS:	HKD-0.240

FY	2023
Przychody:	HKD617 000
Zysk brutto:	HKD55.89M (9 058.51 %)
EPS:	HKD-0.240

FY	2022
Przychody:	HKD51.63M
Zysk brutto:	HKD51.63M (100.00 %)
EPS:	HKD-0.630

FY	2021
Przychody:	HKD0.00
Zysk brutto:	HKD0.00 (0.00 %)
EPS:	HKD-5.90

Financial Reports:

No articles found.

Brii Biosciences Limited

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.